Publications by authors named "S Heidenreich"
Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) exhibit an elevated risk for cardiac arrhythmias, such as bradycardia, which may potentially lead to sudden cardiac death (SCD). While hypoglycemia, defined as a critical drop in glucose levels below the normal range, has long been associated with adverse cardiovascular events, recent studies have highlighted the need for a comprehensive reevaluation of its direct impact on cardiovascular outcomes, particularly in high-risk populations such as those with DM and CKD. In this study, we investigated the association between glucose levels and bradycardia by simultaneously monitoring interstitial glucose (IG) and ECG for 7 days in insulin-treated patients with DM and CKD.
View Article and Find Full Text PDFDespite the introduction of JAK inhibitors, allogeneic hematopoietic cell transplant remains the only potentially curative treatment for patients with myelofibrosis but has considerable treatment-related complications. Whether the incorporation of JAK inhibition into the transplant algorithm leads to improved outcomes is still unclear. Here, we analyzed different transplant platforms in myelofibrosis patients undergoing a first transplant, comparing immune profiles and outcomes of (1) 33 patients continuing JAK inhibition at start of conditioning until stable engraftment (PERI-group), (2) 38 patients receiving JAK inhibition prior to transplant until start of conditioning (PRE-group), and (3) 38 patients that had never received JAK inhibition (NON-group).
View Article and Find Full Text PDFArticle Synopsis
- - This study examined the effectiveness of three different conditioning regimens (Thiotepa-Busulfan, Sequential FLAMSA-Busulfan Fludarabine, and Treosulfan-Fludarabine) prior to allogeneic stem cell transplantation (allo-SCT) in patients with Chronic myelomonocytic leukemia (CMML) from 2006 to 2022.
- - A total of 69 CMML patients participated, with notable variations in donor type and anti-T lymphocyte Globulin use for GVHD prophylaxis across groups.
- - Results suggested that the Thiotepa-Busulfan group experienced better 3-year overall survival (OS) rates (80%) and progression-free survival (
Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission.
Eur J Haematol
January 2025
Article Synopsis
- The optimal TBI dose for patients with high-risk acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (SCT) is still uncertain.
- A retrospective analysis compared outcomes of patients treated with 8 Gy and 12 Gy total body irradiation (TBI) along with fludarabine and PTCy, revealing that while both doses show similar overall and leukemia-free survival, the 12 Gy dose offers better outcomes for MRD-positive patients.
- The study suggests that the 8 Gy TBI results in lower non-relapse mortality but a higher relapse rate compared to 12 Gy, highlighting the need for further research to confirm these results with larger MRD patient groups.
Aims: This study aims to evaluate the cost effectiveness of genetic and genomic testing strategies for the diagnosis of rare developmental disorders in NHS Scotland.
Methods: Six genetic and genomic testing strategies were evaluated using a decision tree model. First-line, second-line and last-resort trio genome sequencing (GS), and second-line and last-resort trio exome sequencing (ES) were compared with standard genetic testing.